GlassScriptPhysician profile
Anthony Leoncavallo
NPI 1992954259
$6,765.07
in general payments reported to CMS, 2019-2025
19 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $797 · 2021: $1,404 · 2022: $832 · 2023: $275 · 2024: $1,115 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,009.02 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,929.60 | 2019-2025 | Tecnis Simplicity, Catalys System, Tecnis Iol |
| Alcon Vision LLC | $556.74 | 2022-2025 | Eysuvis, Tryptyr, Hydrus Microstent |
| Ivantis, INC | $500.00 | 2021 | |
| Glaukos Corporation | $450.24 | 2019-2025 | Idose, Idosetr |
| Bausch & Lomb Americas INC. | $424.32 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $405.89 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $397.90 | 2019-2024 | Cequa |
| Microsurgical Technology, INC. | $361.03 | 2024-2025 | |
| Sight Sciences, INC. | $315.79 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $282.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $258.50 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $247.97 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $203.40 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $174.29 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $94.10 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.81 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $55.40 | 2021-2022 | |
| Shire North American Group INC | $16.71 | 2019 | |
| New World Medical,INC. | $15.88 | 2025 | Via360, Clearpath, Streamline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Leoncavallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.